References
- Gordan LN, Weidner S. Impact of COVID‐19 pandemic on specialty community practices: an oncology perspective. Am J Manag Care. 2020;26(10):SP333.
- Royce TJ, Sanoff HK, Rewari A. Telemedicine for cancer care in the time of COVID‐19. JAMA Oncol. 2020;6(11):1698‐9169.
- Unger JM, Blanke CD, LeBlanc M, et al. Association of the coronavirus disease 2019 (COVID‐19) outbreak with enrollment in cancer clinical trials. JAMA Netw Open. 2020;3(6):e2010651.
- Doherty GJ, Goksu M, de Paula BHR. Rethinking cancer clinical trials for COVID‐19 and beyond. Nat Cancer. 2020;1:568‐572.
- Clinical Trials Transformation Initiative. Join Transforming Trials 2030. Available online at: ctti‐clinicaltrials.org/take‐action/join‐transforming‐trials‐2030. Last accessed March 5, 2021.
- Lopez L III, Hart LH III, Katz MH. Racial and ethnic health disparities related to COVID‐19. JAMA. 2021;325(8):719‐720.
- Balogun OD, Bea VJ, Phillips E. Disparities in cancer outcomes due to COVID‐19—a tale of 2 cities. JAMA Oncol. 2020;6(10):1531‐1532.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7‐33.